Shuo-Feng Yuan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1435166/publications.pdf

Version: 2024-02-01

101543 56724 18,568 85 36 83 citations h-index g-index papers 91 91 91 33024 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Low Environmental Temperature Exacerbates Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Golden Syrian Hamsters. Clinical Infectious Diseases, 2022, 75, e1101-e1111.	5.8	17
2	SPINK6 inhibits human airway serine proteases and restricts influenza virus activation. EMBO Molecular Medicine, 2022, 14, e14485.	6.9	5
3	Orally administered bismuth drug together with <i>N</i> -acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chemical Science, 2022, 13, 2238-2248.	7.4	19
4	COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives. International Journal of Molecular Sciences, 2022, 23, 720.	4.1	32
5	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 2022, 603, 693-699.	27.8	460
6	hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs. Emerging Microbes and Infections, 2022, 11, 519-531.	6.5	8
7	Multiplex metal-detection based assay (MMDA) for COVID-19 diagnosis and identification of disease severity biomarkers. Chemical Science, 2022, 13, 3216-3226.	7.4	5
8	Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. Viruses, 2022, 14, 501.	3.3	15
9	Probable Animal-to-Human Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant AY.127 Causing a Pet Shop-Related Coronavirus Disease 2019 (COVID-19) Outbreak in Hong Kong. Clinical Infectious Diseases, 2022, 75, e76-e81.	5.8	20
10	Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein and Cell, 2022, 13, 940-953.	11.0	23
11	Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. International Journal of Pharmaceutics, 2022, 619, 121704.	5.2	6
12	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals., 2022, 19, 588-601.		27
13	Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo. Cell Research, 2022, 32, 589-592.	12.0	5
14	An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine, 2022, 14, eabn6859.	12.4	31
15	TRAF3 Positively Regulates Host Innate Immune Resistance to Influenza A Virus Infection. Frontiers in Cellular and Infection Microbiology, 2022, 12, 839625.	3.9	5
16	SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. Nature Communications, 2022, 13, 2539.	12.8	22
17	Metal-based strategies for the fight against COVID-19. Chemical Communications, 2022, 58, 7466-7482.	4.1	14
18	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science, 2022, 377, 428-433.	12.6	113

#	Article	IF	CITATIONS
19	Severe Acute Respiratory Syndrome Coronavirus 2 Infects and Damages the Mature and Immature Olfactory Sensory Neurons of Hamsters. Clinical Infectious Diseases, 2021, 73, e503-e512.	5.8	106
20	Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. Clinical Infectious Diseases, 2021, 73, e2946-e2951.	5.8	647
21	SARS-CoV-2 Induces a More Robust Innate Immune Response and Replicates Less Efficiently Than SARS-CoV in the Human Intestines: An ExÂVivo Study With Implications on Pathogenesis of COVID-19. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 771-781.	4.5	41
22	Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening. Journal of Molecular Liquids, 2021, 321, 114784.	4.9	3
23	Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection. Clinical Infectious Diseases, 2021, 72, e659-e662.	5.8	50
24	STAT2-dependent restriction of Zika virus by human macrophages but not dendritic cells. Emerging Microbes and Infections, 2021, 10, 1024-1037.	6.5	12
25	Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerging Microbes and Infections, 2021, 10, 291-304.	6.5	48
26	<i>In silico</i> structure-based discovery of a SARS-CoV-2 main protease inhibitor. International Journal of Biological Sciences, 2021, 17, 1555-1564.	6.4	12
27	Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses. Biomedicines, 2021, 9, 88.	3.2	15
28	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature, 2021, 593, 418-423.	27.8	151
29	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host and Microbe, 2021, 29, 551-563.e5.	11.0	87
30	A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerging Microbes and Infections, 2021, 10, 874-884.	6.5	11
31	A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. European Journal of Medicinal Chemistry, 2021, 215, 113267.	5.5	13
32	Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Science Advances, 2021, 7, .	10.3	48
33	Inhaled Dry Powder Formulation of Tamibarotene, a Broadâ€Spectrum Antiviral against Respiratory Viruses Including SARS oVâ€2 and Influenza Virus. Advanced Therapeutics, 2021, 4, 2100059.	3.2	12
34	Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. Computational and Structural Biotechnology Journal, 2021, 19, 5568-5577.	4.1	3
35	Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nature Communications, 2021, 12, 134.	12.8	112
36	Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters. Clinical Infectious Diseases, 2021, 72, e978-e992.	5.8	84

#	Article	IF	Citations
37	SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. Cell Discovery, 2021, 7, 100.	6.7	29
38	In Silico Structure-Based Design of Antiviral Peptides Targeting the Severe Fever with Thrombocytopenia Syndrome Virus Glycoprotein Gn. Viruses, 2021, 13, 2047.	3.3	0
39	Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine, 2021, 73, 103643.	6.1	127
40	Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters. Cell Reports Medicine, 2020, 1, 100121.	6.5	121
41	Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature, 2020, 586, 113-119.	27.8	672
42	Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nature Microbiology, 2020, 5, 1439-1448.	13.3	140
43	Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε. Journal of Immunology, 2020, 205, 1564-1579.	0.8	30
44	Metabolic Profiling Reveals Significant Perturbations of Intracellular Glucose Homeostasis in Enterovirus-Infected Cells. Metabolites, 2020, 10, 302.	2.9	9
45	Viruses harness $Yxx\tilde{A}^{-}$ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. Science Advances, 2020, 6, eaba7910.	10.3	40
46	Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, 71, 2139-2149.	5.8	501
47	Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacological Research, 2020, 159, 104960.	7.1	56
48	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). Viruses, 2020, 12, 628.	3.3	55
49	Attenuated Interferon and Proinflammatory Response in SARS-CoV-2–Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation. Journal of Infectious Diseases, 2020, 222, 734-745.	4.0	165
50	Zoonotic origins of human coronaviruses. International Journal of Biological Sciences, 2020, 16, 1686-1697.	6.4	680
51	Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clinical Infectious Diseases, 2020, 71, 2428-2446.	5 . 8	839
52	A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, The, 2020, 395, 514-523.	13.7	7,120
53	Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes and Infections, 2020, 9, 221-236.	6.5	2,389
54	Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation. Emerging Microbes and Infections, 2020, 9, 733-746.	6.5	58

#	Article	IF	Citations
55	Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19. Clinical Infectious Diseases, 2020, 71, 1400-1409.	5.8	561
56	Targeting the Inositol-Requiring Enzyme-1 Pathway Efficiently Reverts Zika Virus-Induced Neurogenesis and Spermatogenesis Marker Perturbations. ACS Infectious Diseases, 2020, 6, 1745-1758.	3.8	9
57	Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe, The, 2020, 1, e14-e23.	7.3	683
58	Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy. International Journal of Molecular Sciences, 2019, 20, 392.	4.1	19
59	Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. Viruses, 2019, 11, 73.	3.3	228
60	Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus. Viruses, 2019, 11, 385.	3.3	20
61	Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3â€dependent ubiquitination of ASC. FASEB Journal, 2019, 33, 8865-8877.	0.5	434
62	Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells. International Journal of Molecular Sciences, 2019, 20, 5952.	4.1	27
63	SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nature Communications, 2019, 10, 120.	12.8	192
64	Establishment of a lethal aged mouse model of human respiratory syncytial virus infection. Antiviral Research, 2019, 161, 125-133.	4.1	4
65	Identification and characterization of <code><scp>GLDC</scp></code> as host susceptibility gene to severe influenza. EMBO Molecular Medicine, 2019, 11 , .	6.9	20
66	Inhibitors of Influenza A Virus Polymerase. ACS Infectious Diseases, 2018, 4, 218-223.	3.8	19
67	Large-scale sequence analysis reveals novel human-adaptive markers in PB2 segment of seasonal influenza A viruses. Emerging Microbes and Infections, 2018, 7, 1-12.	6.5	13
68	1899. The Cellular Kinase Inhibitor OSU-03012 Inhibits Enterovirus 71 In Vitro. Open Forum Infectious Diseases, 2018, 5, S545-S545.	0.9	0
69	The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy. Antiviral Research, 2018, 160, 38-47.	4.1	35
70	Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza. Nature Communications, 2018, 9, 2358.	12.8	63
71	Differentiated human airway organoids to assess infectivity of emerging influenza virus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6822-6827.	7.1	215
72	Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. Journal of Biological Chemistry, 2018, 293, 11709-11726.	3.4	153

#	Article	IF	CITATIONS
73	Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Research, 2017, 141, 29-37.	4.1	102
74	Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection inÂvitro and inÂvivo. Antiviral Research, 2017, 145, 33-43.	4.1	99
75	Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. Antiviral Research, 2017, 137, 58-66.	4.1	18
76	PB2 substitutions V598T/I increase the virulence of H7N9 influenza A virus in mammals. Virology, 2017, 501, 92-101.	2.4	34
77	Antibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic H1N1 Influenza Virus Play Detrimental Roles in H1N1-Infected Mice. Frontiers in Immunology, 2017, 8, 317.	4.8	32
78	PA N substitutions A37S, A37S/I61T and A37S/V63I attenuate the replication of H7N7 influenza A virus by impairing the polymerase and endonuclease activities. Journal of General Virology, 2017, 98, 364-373.	2.9	5
79	Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts. Virology, 2016, 498, 1-8.	2.4	12
80	Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza A virus. Scientific Reports, 2016, 6, 37800.	3.3	25
81	A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase. Scientific Reports, 2016, 6, 22880.	3.3	37
82	A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication. Journal of Antimicrobial Chemotherapy, 2016, 71, 2489-2497.	3.0	30
83	Peptide-Mediated Interference of PB2-elF4G1 Interaction Inhibits Influenza A Viruses' Replication in Vitro and in Vivo. ACS Infectious Diseases, 2016, 2, 471-477.	3.8	8
84	Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase. Antiviral Research, 2016, 125, 34-42.	4.1	41
85	Cross-Protection of Influenza A Virus Infection by a DNA Aptamer Targeting the PA Endonuclease Domain. Antimicrobial Agents and Chemotherapy, 2015, 59, 4082-4093.	3.2	38